A
2.06
0.17 (8.99%)
| Previous Close | 1.89 |
| Open | 1.90 |
| Volume | 938,515 |
| Avg. Volume (3M) | 1,272,533 |
| Market Cap | 201,741,152 |
| Price / Sales | 2.71 |
| Price / Book | 1.47 |
| 52 Weeks Range | |
| Earnings Date | 25 Feb 2025 - 3 Mar 2025 |
| Profit Margin | -257.54% |
| Operating Margin (TTM) | -301.32% |
| Diluted EPS (TTM) | -1.71 |
| Quarterly Revenue Growth (YOY) | 68.40% |
| Total Debt/Equity (MRQ) | 29.12% |
| Current Ratio (MRQ) | 3.29 |
| Operating Cash Flow (TTM) | -220.95 M |
| Levered Free Cash Flow (TTM) | -66.92 M |
| Return on Assets (TTM) | -19.25% |
| Return on Equity (TTM) | -112.55% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Alector, Inc. | Bearish | Bearish |
AIStockmoo Score
1.3
| Analyst Consensus | 1.0 |
| Insider Activity | NA |
| Price Volatility | 3.0 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | -0.5 |
| Average | 1.25 |
|
Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 9.97% |
| % Held by Institutions | 96.64% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 35.00 (HC Wainwright & Co., 1,599.03%) | Buy |
| Median | 4.50 (118.45%) | |
| Low | 3.00 (Morgan Stanley, 45.63%) | Sell |
| Average | 11.75 (470.39%) | |
| Total | 2 Buy, 1 Hold, 1 Sell | |
| Avg. Price @ Call | 3.19 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Stifel | 16 Dec 2024 | 4.00 (94.17%) | Hold | 1.98 |
| BTIG | 26 Nov 2024 | 5.00 (142.72%) | Buy | 2.57 |
| Morgan Stanley | 26 Nov 2024 | 3.00 (45.63%) | Sell | 2.57 |
| HC Wainwright & Co. | 07 Nov 2024 | 35.00 (1,599.03%) | Buy | 5.64 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 13 Jan 2025 | Announcement | Alector Reports on Recent Progress and Outlines Strategic Priorities for 2025 |
| 25 Nov 2024 | Announcement | Alector Announces Results from AL002 INVOKE-2 Phase 2 Trial in Individuals with Early Alzheimer’s Disease and Provides Business Update |
| 14 Nov 2024 | Announcement | Alector Secures Flexible Credit Facility for Up to $50 Million From Hercules Capital |
| 06 Nov 2024 | Announcement | Alector Reports Third Quarter 2024 Financial Results and Provides Business Update |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |